JP2018504450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504450A5 JP2018504450A5 JP2017546034A JP2017546034A JP2018504450A5 JP 2018504450 A5 JP2018504450 A5 JP 2018504450A5 JP 2017546034 A JP2017546034 A JP 2017546034A JP 2017546034 A JP2017546034 A JP 2017546034A JP 2018504450 A5 JP2018504450 A5 JP 2018504450A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- composition according
- pharmaceutical composition
- pharmaceutical
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 230000001225 therapeutic effect Effects 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 5
- 230000001988 toxicity Effects 0.000 claims 5
- 231100000419 toxicity Toxicity 0.000 claims 5
- 229910010272 inorganic material Inorganic materials 0.000 claims 3
- 229910052751 metal Inorganic materials 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000011147 inorganic material Substances 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- 229910002706 AlOOH Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910002588 FeOOH Inorganic materials 0.000 claims 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229910004298 SiO 2 Inorganic materials 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- CUPCBVUMRUSXIU-UHFFFAOYSA-N [Fe].OOO Chemical compound [Fe].OOO CUPCBVUMRUSXIU-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 claims 1
- HDMKAUUMGFGBRJ-UHFFFAOYSA-N iron;dihydrate Chemical compound O.O.[Fe] HDMKAUUMGFGBRJ-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000002082 metal nanoparticle Substances 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- 229910052976 metal sulfide Inorganic materials 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229910052814 silicon oxide Inorganic materials 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306874.0 | 2014-11-25 | ||
| EP14306874 | 2014-11-25 | ||
| PCT/EP2015/077446 WO2016083343A1 (en) | 2014-11-25 | 2015-11-24 | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504450A JP2018504450A (ja) | 2018-02-15 |
| JP2018504450A5 true JP2018504450A5 (enExample) | 2019-01-31 |
| JP6836510B2 JP6836510B2 (ja) | 2021-03-03 |
Family
ID=52013981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546034A Active JP6836510B2 (ja) | 2014-11-25 | 2015-11-24 | 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10391058B2 (enExample) |
| EP (1) | EP3229776B1 (enExample) |
| JP (1) | JP6836510B2 (enExample) |
| AR (1) | AR102781A1 (enExample) |
| DK (1) | DK3229776T3 (enExample) |
| ES (1) | ES2951598T3 (enExample) |
| FI (1) | FI3229776T3 (enExample) |
| HU (1) | HUE062561T2 (enExample) |
| LT (1) | LT3229776T (enExample) |
| PL (1) | PL3229776T3 (enExample) |
| PT (1) | PT3229776T (enExample) |
| TW (1) | TW201628654A (enExample) |
| WO (1) | WO2016083343A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA38687A1 (fr) | 2013-05-30 | 2017-12-29 | Nanobiotix | Composition pharmaceutique, préparation et utilisations de celle-ci |
| US11304902B2 (en) | 2014-11-25 | 2022-04-19 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
| TW201628656A (zh) | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備與用途 |
| ES2951598T3 (es) * | 2014-11-25 | 2023-10-23 | Curadigm Sas | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos |
| EP3229843B1 (en) | 2014-11-25 | 2020-01-01 | Curadigm Sas | Pharmaceutical composition, preparation and uses thereof |
| MA43100A (fr) | 2015-05-28 | 2018-09-05 | Nanobiotix | Nanoparticules à utiliser en tant que vaccin thérapeutique |
| CN115137822B (zh) * | 2022-06-13 | 2023-06-23 | 武汉大学中南医院 | 一种光热热电一体化的抗肿瘤植入体的制备方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| AU4821697A (en) | 1996-10-18 | 1998-05-15 | Wayne State University | 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice |
| JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
| JP2001515035A (ja) | 1997-08-19 | 2001-09-18 | ワーナー−ランバート・カンパニー | 薬剤の経口生体利用性を高めるベルガモッチンを含有する組成物 |
| US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| ES2253398T3 (es) * | 2000-06-30 | 2006-06-01 | Inex Pharmaceuticals Corp. | Camptotecinas liposomales mejoradas y sus usos. |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| US9750821B2 (en) | 2003-12-22 | 2017-09-05 | Bracco Suisse S.A. | Gas-filled microvesicle assembly for contrast imaging |
| EP1720521A4 (en) * | 2004-02-10 | 2008-11-05 | Barnes Jewish Hospital | IMPROVED EFFICIENCY AND SAFETY OF TARGETED MEANS WITH DECOY SYSTEMS |
| US20060264804A1 (en) | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
| WO2006127962A2 (en) * | 2005-05-25 | 2006-11-30 | Becton, Dickinson And Comapny | Particulate formulations for intradermal delivery of biologically active agents |
| DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| WO2007122956A1 (ja) | 2006-03-24 | 2007-11-01 | Toto Ltd. | 酸化チタン複合体粒子、その分散液、およびそれらの製造方法 |
| JP2009536151A (ja) | 2006-03-30 | 2009-10-08 | 富士フイルム株式会社 | ナノ粒子 |
| EP1852107A1 (en) | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
| EP2019665B1 (en) | 2006-05-04 | 2018-09-19 | Reformpharm Pty Ltd | Drug release from nanoparticle-coated capsules |
| AU2008288917A1 (en) | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| US20100272639A1 (en) | 2007-12-21 | 2010-10-28 | John Robert Dutcher | Polysaccharide nanoparticles |
| CA2716347C (en) | 2008-02-21 | 2017-06-20 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| US20130023714A1 (en) | 2008-10-26 | 2013-01-24 | Board Of Regents, The University Of Texas Systems | Medical and Imaging Nanoclusters |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| EP2537530A4 (en) | 2010-02-17 | 2015-12-16 | Nat Univ Corp Univ Kobe | RADIATION MEANS |
| BR112012024349A2 (pt) | 2010-03-26 | 2016-05-24 | Abraxis Bioscience Llc | métodos de tratamento de carcinoma hepatocelular |
| GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| WO2012051220A1 (en) | 2010-10-11 | 2012-04-19 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| EP3192800A1 (en) | 2010-12-17 | 2017-07-19 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| EP2670394B1 (en) | 2011-01-31 | 2018-11-21 | Nanobiotix | Nanoparticles delivery systems, preparation and uses thereof |
| EP2670393B8 (en) | 2011-01-31 | 2016-10-05 | Nanobiotix | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles. |
| WO2013059295A2 (en) | 2011-10-17 | 2013-04-25 | Trustees Of Boston University | Polymeric depots for localization of an agent to biological sites |
| CN102532154B (zh) | 2012-01-11 | 2014-05-14 | 昆明医学院 | 隆萼当归线型呋喃香豆素化合物及其应用 |
| WO2014039874A2 (en) | 2012-09-07 | 2014-03-13 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| MA38687A1 (fr) * | 2013-05-30 | 2017-12-29 | Nanobiotix | Composition pharmaceutique, préparation et utilisations de celle-ci |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| EP3229843B1 (en) | 2014-11-25 | 2020-01-01 | Curadigm Sas | Pharmaceutical composition, preparation and uses thereof |
| CN107106505A (zh) | 2014-11-25 | 2017-08-29 | 纳米生物技术公司 | 药物组合物、其制备和用途 |
| US11304902B2 (en) | 2014-11-25 | 2022-04-19 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
| TW201628656A (zh) | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備與用途 |
| ES2951598T3 (es) * | 2014-11-25 | 2023-10-23 | Curadigm Sas | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos |
-
2015
- 2015-11-24 ES ES15800777T patent/ES2951598T3/es active Active
- 2015-11-24 PT PT158007773T patent/PT3229776T/pt unknown
- 2015-11-24 US US15/529,101 patent/US10391058B2/en active Active
- 2015-11-24 HU HUE15800777A patent/HUE062561T2/hu unknown
- 2015-11-24 PL PL15800777.3T patent/PL3229776T3/pl unknown
- 2015-11-24 FI FIEP15800777.3T patent/FI3229776T3/fi active
- 2015-11-24 TW TW104139005A patent/TW201628654A/zh unknown
- 2015-11-24 JP JP2017546034A patent/JP6836510B2/ja active Active
- 2015-11-24 LT LTEPPCT/EP2015/077446T patent/LT3229776T/lt unknown
- 2015-11-24 DK DK15800777.3T patent/DK3229776T3/da active
- 2015-11-24 WO PCT/EP2015/077446 patent/WO2016083343A1/en not_active Ceased
- 2015-11-24 AR ARP150103849A patent/AR102781A1/es unknown
- 2015-11-24 EP EP15800777.3A patent/EP3229776B1/en active Active
-
2019
- 2019-08-26 US US16/550,342 patent/US11471410B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504450A5 (enExample) | ||
| JP2016522833A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| JP2016513657A5 (enExample) | ||
| JP2017514800A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| HK1222563A1 (zh) | 药物组合物、制备及其用途 | |
| WO2009053644A3 (fr) | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants | |
| HK1212616A1 (zh) | 多孔载体颗粒和微粒化药物的可吸入团聚物 | |
| NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
| JP2011505440A5 (enExample) | ||
| JP2010523696A5 (enExample) | ||
| NZ769187A (en) | Pharmaceutical composition, preparation and uses thereof | |
| JP2019521180A5 (enExample) | ||
| JP2018538273A5 (enExample) | ||
| RU2018119680A (ru) | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина | |
| AR102781A1 (es) | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos | |
| JP2018527287A5 (enExample) | ||
| JP2012529293A5 (enExample) | ||
| JP2016511747A5 (enExample) | ||
| Vanea et al. | XPS and Raman study of zinc containing silica microparticles loaded with insulin | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| WO2012007913A3 (en) | Oral administration forms for controlled release of rifampicin or other antibiotics for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract | |
| JP2017514858A5 (enExample) |